Arrowstreet Capital
ATNM icon

Arrowstreet Capital’s Actinium Pharmaceuticals ATNM Stock Holding History

Arrowstreet Capital’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-28,500
Closed -$276K – 2274
2020
Q3 		$276K Buy
28,500
+23,450
+464% +$259K ﹤0.01% 2154
2020
Q2 		$53K Buy
+5,050
New +$38.2K ﹤0.01% 2252

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arrowstreet Capital's ATNM Position: Q4 2020 in Review

Arrowstreet Capital sold out of Actinium Pharmaceuticals (ATNM) in Q4 2020, closing a stake of 28,500 shares — an estimated $276K sold.

Arrowstreet Capital first reported a position in ATNM in Q2 2020 and held it in 2 quarters. The position peaked at $276K in Q3 2020. 48 funds tracked by Wall St. Rank hold ATNM as of Q4 2020.

  • Arrowstreet Capital reported no remaining Actinium Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 28,500 Actinium Pharmaceuticals shares in Q4 2020, an estimated $276K.
  • Arrowstreet Capital first reported a position in Actinium Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Arrowstreet Capital's Actinium Pharmaceuticals position peaked at $276K in Q3 2020.
  • 48 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2020.

Based on Arrowstreet Capital's 13F filing for Q4 2020, filed 12 Feb 2021.